Globalworld globe
United Kingdom
North America
Europe
  • facebook
  • linkedin
Medical Developments International
  • Home
  • Products
    • Asthma & COPD
  • About
    • Distributor Information
    • Careers
    • Associations
  • Investors/Media
    • Financial Reports
    • Board of Directors/Management
    • Corporate Governance
    • Media Centre
    • Diversity Policy
    • Share Trading Policy
  • Contact

News

Penthrox Launch in the UK and Pricing Approval for Ireland

Jan 27, 2016Mark EdwardsNews

27 January 2016

ASX ANNOUNCEMENT

Penthrox Launch in the UK and Pricing Approval for Ireland

Medical Developments International Limited (ASX: MVP) is delighted to announce that its fast acting, category leading non-narcotic analgesic, Penthrox, was launched in the UK by Galen Limited on 25 January 2016.

In addition to the launch in the UK, MVP is delighted to announce Penthrox has received full pricing reimbursement approval from the Irish Medicine’s Board, which is another significant achievement.

For more information please refer to the following link ASX Announcement_Penthrox Launch in the UK and Pricing Approval for Ireland

Contact Us

for information on our range of products

Find a distributor

in our global network

Investors

invest in a company with
innovative foresight

News

  • FY23 ASX Announcement

    31 August 2023 ASX Announ...

  • Medical Developments International Ltd awarded up to $1.5M in funding for next generation Penthrox® device

    Media Announcment Medical...

  • FY23 Half Year ASX Announcement

    24 February 2023 ASX Anno...

Healthcare Professional Registration

Login to access healthcare professional resources



Remember Me

Forgot password? | Register

Medical Developments International

Address:
4 Caribbean Drive, Scoresby,
Victoria, 3179
Australia
Phone: +61 3 9547 1888
Email: [email protected]
ABN: 14 106 340 667
For Medical Enquiries:

Phone: 1800 PENTHROX (1800 736 847)
Email: [email protected]

Email Newsletter